These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6405546)

  • 1. [Clinico-experimental long-term study on the combined effect of clofibrin and nicotinic acid on abnormal fatty acid patterns in lipid metabolism disorders in the aged].
    Reuter W
    Z Alternsforsch; 1983; 38(1):57-62. PubMed ID: 6405546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modification of pathologic fatty acid patterns in old age by combined clofibrinic and nicotinic acid treatment].
    Reuter W
    Z Alternsforsch; 1983; 38(5):383-8. PubMed ID: 6659567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1982 Oct; 37(20):682-8. PubMed ID: 6818779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
    Reuter W
    Z Alternsforsch; 1982; 37(6):409-16. PubMed ID: 7164480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of various modes of therapy on the fatty acid spectrum in hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1977 Jul; 32(13):203-5. PubMed ID: 930182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fatty acid metabolism in primary hyperlipoproteinemia (HLP) (author's transl)].
    Reuter W
    Dtsch Z Verdau Stoffwechselkr; 1979; 39(3):124-9. PubMed ID: 520271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG; Hutt V; Klör HU; Ditschuneit H
    Artery; 1980; 8(6):519-29. PubMed ID: 7259531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
    Vessby B; Lithell H; Gustafsson IB; Boberg J
    Atherosclerosis; 1980 Jan; 35(1):51-65. PubMed ID: 6989377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipoproteins and fatty acids--hyperlipoproteinemia and arteriosclerosis].
    Reuter W
    Z Gesamte Inn Med; 1978 Sep; 33(17):622-5. PubMed ID: 706497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of postnatal age and diet on the fatty acid composition of plasma lipid fractions in preterm infants.
    Pita ML; Girón MD; Pérez-Ayala M; DeLucchi C; Martínez Valverde A; Gil A
    Clin Physiol Biochem; 1989; 7(5):238-48. PubMed ID: 2805572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term effect of polyenic-fatty-acids-enriched diet on the relations of fatty acids and glycerophospholipids in 50- to 60-year-old HLP patients].
    Reuter W; Heybey U
    Z Alternsforsch; 1984; 39(2):63-6. PubMed ID: 6730529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W; Zschiedrich M
    Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in fatty acid composition of the single platelet phospholipids induced by pantethine treatment.
    Gensini GF; Prisco D; Rogasi PG; Matucci M; Neri Serneri GG
    Int J Clin Pharmacol Res; 1985; 5(5):309-18. PubMed ID: 4066081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipid-reducing basic diet and serum fatty acid levels].
    Reuter W
    Z Gesamte Inn Med; 1980 Sep; 35(18):701-6. PubMed ID: 7445612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum profile of non-esterified fatty acids (NEFA) in patients with hyperlipoproteinemia under xantinol--nicotinate (XN) medication.
    Haacke H; Parwaresch MR; Mäder C
    Atherosclerosis; 1980 Sep; 37(1):77-85. PubMed ID: 7426090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.